UBS raises Insmed stock price target to $110

On Thursday, UBS maintained a positive outlook on Insmed (NASDAQ:INSM) shares, raising the price target to $110 from $105 while keeping a Buy rating on the stock. Currently trading at $77.12 with a market capitalization of $14 billion, the company has delivered an impressive 177% return over the past year. The price target adjustment comes in anticipation of Phase 2 data for treprostinil palmitil inhalation powder (TPIP) in Pulmonary Arterial Hypertension (PAH), expected around mid-2025. According to InvestingPro analysis, the stock appears slightly overvalued at current levels.

The Phase 2 trial will assess Insmed’s TPIP, a prodrug of treprostinil, in a study involving 102 participants with PAH. UBS analysts have conducted a scenario analysis on their Discounted Cash Flow (DCF) model to forecast potential stock reactions based on the upcoming trial results. With a strong analyst consensus rating of 1.33 (where 1 is Strong Buy) and price targets ranging from $67 to $108, Wall Street remains optimistic about the company’s prospects despite its current unprofitability.

According to UBS, prostacyclins, the class of drugs to which treprostinil belongs, have historically shown a capacity to reduce pulmonary vascular resistance (PVR) by approximately 20%. The analysts note that a 20-25% reduction in PVR would be meaningful for the study, potentially positioning TPIP as the preferred inhaled prostacyclin treatment for PAH.

The analysts also outlined their expectations for the trial, stating that a PVR reduction of less than 20% would be a disappointment. Conversely, they described a "blue sky scenario" where a 25-30% PVR reduction could be achieved, which would approach the target product profile of sotatercept, a competing treatment that has demonstrated a PVR reduction of 33.9%.

UBS’s report details key considerations for the Phase 2 trial, emphasizing the significance of the efficacy bar set for TPIP. The firm’s analysis will help inform investors of the potential outcomes and their implications for Insmed’s stock performance as the data release approaches. The company maintains healthy liquidity with a current ratio of 5.45 and has achieved 19% revenue growth in the last twelve months. For deeper insights into Insmed’s financial health, growth prospects, and comprehensive analysis, investors can access the full research report on InvestingPro, which offers exclusive metrics and expert analysis for over 1,400 US stocks.

In other recent news, Insmed Incorporated reported its fourth-quarter 2024 earnings, revealing a larger-than-expected loss per share of -1.32, missing the anticipated -1.18, while revenue exceeded forecasts, reaching $104.44 million against the expected $97.68 million. The company also announced a robust 19% year-over-year growth in global net revenue for 2024, driven by significant contributions from the U.S. and Japan. Insmed’s earnings call highlighted the potential launch of brensocatib, with the FDA setting a PDUFA date for August 12, 2025, and no advisory committee meeting planned, suggesting a straightforward review process. RBC Capital initiated coverage on Insmed, assigning an Outperform rating and a price target of $100, citing the potential success of brensocatib in treating bronchiectasis. UBS also raised its price target for Insmed to $105, maintaining a Buy rating, reflecting confidence in the company’s growth prospects. Insmed’s management expressed optimism about the company’s pipeline, including the TPIP program, with anticipated data readouts expected to drive growth. These developments position Insmed favorably as it aims to address significant unmet medical needs in the biotech sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.